Home Procedures TACE for Liver Cancer

TACE — Chemoembolisation for Liver Cancer

The world's most widely used locoregional treatment for liver cancer delivering high-dose chemotherapy directly to the tumour while cutting off its blood supply.

Oncology IR Procedure

What is TACE (Chemoembolisation)?

Transarterial Chemoembolisation (TACE) is the globally established standard of care for intermediate-stage hepatocellular carcinoma (HCC) and is also used for liver metastases. A catheter is navigated through the femoral artery into the hepatic artery branches supplying the tumour, where a combination of chemotherapy drugs and embolic particles is injected. This simultaneously delivers chemotherapy at concentrations up to 100 times higher than systemic treatment directly to the tumour, while completely cutting off its blood supply inducing extensive tumour cell death while sparing normal liver tissue, which has a dual blood supply from the portal vein.

Who is this procedure for?

TACE is recommended for patients with unresectable hepatocellular carcinoma (HCC) and preserved liver function (Child-Pugh A or B), patients with multinodular disease or tumours too large for ablation alone, and selected patients with liver-dominant metastases (particularly from colorectal, neuroendocrine, or breast primaries). It is also used as a bridge therapy to liver transplantation to prevent tumour progression while awaiting a donor organ, and to downstage large HCCs to make them eligible for curative surgery or transplant.

How is the procedure performed?

  • A thin catheter is introduced through the femoral artery in the groin under local anaesthesia and navigated under X-ray guidance into the hepatic artery.
  • The catheter is advanced super-selectively into the specific branch of the hepatic artery feeding the tumour, guided by real-time fluoroscopy.
  • A hepatic angiogram (contrast X-ray) is performed to map the tumour's blood supply precisely and confirm optimal catheter position.
  • A carefully prepared mixture of chemotherapy (doxorubicin, cisplatin, or drug-eluting microspheres) and embolic particles is injected slowly into the feeding artery.
  • Completion angiography confirms successful tumour devascularisation the tumour's blood supply is now blocked.
  • The catheter is removed; the patient is admitted overnight and typically discharged the following morning after observation.
TACE (Chemoembolisation) – Dr. Gurucharan S Shetty, Bangalore

Benefits of TACE (Chemoembolisation)

Targeted Therapy With Minimal Side Effects

Chemotherapy delivered directly to the tumour at far higher local concentrations dramatically reduces systemic toxicity hair loss, severe nausea, and immune suppression are significantly less common than with IV chemotherapy.

Proven Survival Benefit in Liver Cancer

TACE is the only locoregional therapy proven in randomised controlled trials to improve overall survival in intermediate-stage HCC, endorsed by AASLD, EASL, and all major international liver cancer guidelines.

Bridge to Curative Treatment

TACE can shrink and control tumours sufficiently to allow patients initially deemed inoperable to become eligible for surgical resection or liver transplantation offering a pathway to potential cure.

Frequently Asked Questions

Most patients require 2–4 sessions spaced 4–8 weeks apart, guided by imaging response (CT or MRI with RECIST/mRECIST criteria) after each session. The goal is complete devascularisation of all target lesions. Sessions continue as long as the tumour responds and liver function remains adequate.
Post-embolisation syndrome fever, fatigue, nausea, and right upper quadrant pain lasting 3–7 days is common and expected after TACE. It reflects tumour cell death (a desired effect) and is managed effectively with prescribed pain relief, anti-nausea medication, and adequate hydration. Most patients feel back to their baseline within 1–2 weeks.
TACE is primarily a disease-control treatment. It can induce complete tumour necrosis in a subset of patients with small HCCs, but it is most often used to control disease progression, extend survival, maintain transplant eligibility, or downstage tumours for curative surgery. Dr. Shetty will discuss realistic treatment goals based on your specific tumour stage and liver function.
Book Consultation with Dr. Shetty

Ready to discuss your case?

Consult with Dr. Gurucharan S Shetty for expert advice on whether this procedure is right for you.

Book Appointment